Supplementary Figure 1

Similar documents
SUPPLEMENTARY INFORMATION

Time after injection (hours) ns ns

Supplementary Figure S1. Effect of Glucose on Energy Balance in WT and KHK A/C KO

Supplementary Figure 1: Additional metabolic parameters of obesity mouse models and controls. (a) Body weight, (b) blood glucose and (c) insulin

Fig. S1. REGN1500 reduces plasma levels of cholesterol, TG and NEFA in WT and Ldlr -/- mice. (A) WT

Supplemental Fig. 1. Changes in fat and lean mass determined by DEXA. Fat mass in high fat-fed

Supplementary Figure 1. DNA methylation of the adiponectin promoter R1, Pparg2, and Tnfa promoter in adipocytes is not affected by obesity.

1.5 ASK1KO fed. fasted 16 hrs w/o water. Fed. 4th. 4th WT ASK1KO N=29, 11(WT), ,5(ASK1KO) ASK1KO ASK1KO **** Time [h]

Supplementary Figure 1

glpx Rv1100 Probe 4.4 kb 75 kda 50 kda 37 kda 25 kda 20 kda

Supplemental information

The role of apolipoprotein D in lipid metabolism and metabolic syndrome

Supplementary Table 1. Metabolic parameters in GFP and OGT-treated mice

Supplementary Figure 1

Control 7 d cold 7 d CL

Type of file: PDF Title of file for HTML: Supplementary Information Description: Supplementary Figures and Supplementary Table.

Male 30. Female. Body weight (g) Age (weeks) Age (weeks) Atg7 f/f Atg7 ΔCD11c

SUPPLEMENTARY INFORMATION

* * A3027. A4623 e A3507 A3507 A3507

Supplementary Table 2. Plasma lipid profiles in wild type and mutant female mice submitted to a HFD for 12 weeks wt ERα -/- AF-1 0 AF-2 0

control kda ATGL ATGLi HSL 82 GAPDH * ** *** WT/cTg WT/cTg ATGLi AKO/cTg AKO/cTg ATGLi WT/cTg WT/cTg ATGLi AKO/cTg AKO/cTg ATGLi iwat gwat ibat

Supplementary Figure 1

Supplementary Figure S1

Supplementary Material. Contents include:

Cytochrome-C (rat, mouse) forward GGAGGCAAGCATAAGACTGG. mouse hexokinase 2 gene, intron 9 reverse GGGAACACAAAAGACCTCTTCTGG

ZL ZDF ZDF + E2 *** Visceral (g) ZDF

SUPPLEMENTARY DATA. Supplementary Table 1. Primer sequences for qrt-pcr

Supplementary Figure S1. TRAIL-induced necroptosis at acidic phe is dependent on

Physiological Chemistry II Exam IV Dr. Melissa Kelley April 13, 2004

Supplementary Fig. 1 eif6 +/- mice show a reduction in white adipose tissue, blood lipids and normal glycogen synthesis. The cohort of the original

Can physical exercise and exercise mimetics improve metabolic health in humans?

Supplementary Table 1. Blood glucose levels in male Zucker fa/fa rat during 1 month treatment with either vehicle or Chinese medicine (JCU).

Supplementary Table 1.

Quantitative Real-Time PCR was performed as same as Materials and Methods.

GPR120 *** * * Liver BAT iwat ewat mwat Ileum Colon. UCP1 mrna ***

Supplementary Figure 1.

Effects of sitagliptin on cardiac metabolism in mice

SUPPLEMENTARY DATA. Nature Medicine: doi: /nm.4171

SUPPLEMENTARY INFORMATION

SITA 100 mg (n = 378)

SUPPLEMENTARY INFORMATION

Supplemental Fig. 1. Relative mrna Expression. Relative mrna Expression WT KO WT KO RT 4 0 C

SUPPLEMENTARY FIGURES

Supplemental Information

Supplementary Figure 1. A. Bar graph representing the expression levels of the 19 indicated genes in the microarrays analyses comparing human lung

Supporting information

Dietary α-linolenic acid-rich flaxseed oil prevents against alcoholic hepatic steatosis

SUPPLEMENTARY INFORMATION

Integrative Metabolism: Significance

Supplementary Materials for

B. SDS-PAGE. Western blot MW (kda) Supplementary Information. Supplementary Figure 1. MW (kda) Glutelin. Prolamin. 3 E.coli. 3 E.

islets scored 1 week month months

days days and gbt-i.cd Recipient 20

Light triggers PILS-dependent reduction in nuclear auxin signalling for growth transition

Supplementary Materials: Decrease in Circulating Fatty Acids is Associated with Islet Dysfunction in Chronically Sleep-Restricted Rats

Metabolic Syndrome. DOPE amines COGS 163

Supplemental Table 1 Primer sequences (mouse) used for real-time qrt-pcr studies

SUPPLEMENTARY DATA Supplementary Figure 1. Body weight and fat mass of AdicerKO mice.

Supplementary Figure 1

IL-6Rα IL-6RαT-KO KO. IL-6Rα f/f bp. f/f 628 bp deleted 368 bp. 500 bp

a Supplementary Figure 1 Celastrol Withaferin A Individual drugs

Supplementary Information Titles Journal: Nature Medicine

SUPPLEMENTARY MATERIAL

SUPPLEMENTARY INFORMATION

IP: anti-gfp VPS29-GFP. IP: anti-vps26. IP: anti-gfp - + +

Supplemental Information. Increased 4E-BP1 Expression Protects. against Diet-Induced Obesity and Insulin. Resistance in Male Mice

1,8 1,6 1,4 1,2 1. EE/g lean mass 0,8 0,6 0,4 0,2. Ambulatory locomotor activity. (beam brakes/48h) V MCH MCHpf 0,86 0,85 0,84 0,83 0,82 0,81 0,8

HIV long term complications

Nature Medicine: doi: /nm.3891

Supplementary Figure 1. Western blot of hippocampal lysates from WT and Adcy1 KO mice demonstrates the specificity of the ADCY1 antibody.

Supplemental Information Supplementary Table 1. Tph1+/+ Tph1 / Analyte Supplementary Table 2. Tissue Vehicle LP value

Supplementary Figure 1. Antibiotic partially rescues mice from sepsis. (ab) BALB/c mice under CLP were treated with antibiotic or PBS.

Supplementary Information. Glycogen shortage during fasting triggers liver-brain-adipose. neurocircuitry to facilitate fat utilization

Role of the Pyruvate

Supplementary information Novel VCP modulators mi2gate major pathologies of rd10, a mouse model of re2ni2s pigmentosa

Hmgcoar AGCTTGCCCGAATTGTATGTG TCTGTTGTAACCATGTGACTTC. Cyp7α GGGATTGCTGTGGTAGTGAGC GGTATGGAATCAACCCGTTGTC

AdPLA ablation increases lipolysis and prevents obesity induced by high fat feeding or leptin deficiency

[U- 13 C5] glutamine. Glutamate. Acetyl-coA. Citrate. Citrate. Malate. Malate. Isocitrate OXIDATIVE METABOLISM. Oxaloacetate CO2.

Genetics Test Review

Supplementary Material

BIOL212 Biochemistry of Disease. Metabolic Disorders - Obesity

a Anti-Dab2 RGD Merge

A Central Role of MG53 in Metabolic Syndrome. and Type-2 Diabetes

Supplementary Figure 1

Supplementary Table 1. Criteria for selection of normal control individuals among healthy volunteers

Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients

Modifications of Pyruvate Handling in Health and Disease Prof. Mary Sugden

Supplementary Information

perk/erk STAT5B

1. Materials and Methods 1.1 Animals experiments process The experiments were approved by the Institution Animal Ethics Committee of Jilin University

Ct=28.4 WAT 92.6% Hepatic CE (mg/g) P=3.6x10-08 Plasma Cholesterol (mg/dl)

Regulation of Metabolism

Ctrl CCT7 CCT2 GAPDH * * ** ** * Ctrl Size of LC3 dots (a.u.) mrfp GFP mrfp-gfp-lc3 CCT5 KD CCT7 KD

7.06 Cell Biology EXAM #3 April 24, 2003

Successful completion of Phase I clinical trial of AMPK activator O304

Males- Western Diet WT KO Age (wks) Females- Western Diet WT KO Age (wks)

BMI risk SNPs associate with increased CADM1 and CADM2 expression in the cerebellum of human subjects.

Supplementary information

Supplementary Information

ALT (U/L) (Relative expression) HDL (mm) (Relative expression) ALT (U/L) (Relative expression)

Transcription:

Supplementary Figure 1 a OD c. 1. 1... Time [min] 1 p<.1 H O (LB) 1 µm GlcN (LB) H O (NGM) 1 µm GlcN (NGM) H O (1) 1 µm GlcN (1) 1 1 3 3 d 1 p<.1 Douling Time [min] H O () 1 µm GlcN () 1 1 3 3 LB e 1 p<.1 H O (3) 1 µm GlcN (3) 1 1 3 3 f 1 p<. H O (linded) 1 µm GlcN (linded) 1 1 3 3 g 1 p<.1 H O (HIT ac) 1 µm GlcN (HIT ac) 1 3 Supplementary Figure 1: Details of C. elegans lifespan assays Growth characteristics of E. coli OP in oth LB and NGM media, respectively, depicted a as a photometrically determined growth curve and organismal douling time (for LB media only, since no significant growth in NGM media). c-e Individual lifespan results of data summarized in Fig. 1 (p<.1, log-rank test, n=1 each). f Typical lifespan result for experimental setting where experimenter was unaware of GlcN content or control, respectively (p<., log-rank test, n=1). g Lifespan result using heat-inactivated acteria (p<.1, log-rank test, n=1). Controls are always depicted in lack and grey color, whereas GlcN-treatment is depicted in red. The ars represent the mean + s.d.

Supplementary Figure a c d e f p interact. <.1 p interact. =. p interact. =.31 Food uptake [g/d] 3 1 * Food uptake [g/d] 3 1 Plasma GlcN [µmol/l] 3 1 * Plasma GlcN [µ mol/l] 3 1 ** GlcN--PO * GlcN--PO g h i j p interact. =.19 p interact. =.13 Body Mass [g] 3 1 Body Mass [g] 33 3 1 33 Fat [g] 1 1 Fat [g] 1 1 33 33 k l m n p interact =. p interact =.3 Lean Mass [g] 3 1 33 Lean Mass [g] 3 1 33 mtdna / ndna 1. ***..... mtdna / ndna 1...... p interact =. o p EE / MBM [kj/h/kg] 11 1 9 7 p=.9 1 Time [hrs] EE / MBM [kj/h/kg] 1 9 7 1 Time [hrs]

Supplementary Figure continued Supplementary Figure : Sex specific results of mouse phenotyping part 1 a Food uptake of a female (lue: p<., Student s t-test, n= 1 control mice and n= 1 GlcN-fed mice) and male C7BL/-NRj mice chronically exposed to GlcN (red), and respective controls (lack: interaction etween gender and treatment, two-way ANOVA, F (1,33)=., p<.1, n= 17 control mice and n= GlcN-fed mice). c Plasma levels of GlcN in female (lue: p<., Student s t-test, n= 1 control mice and n= 9 GlcN-fed mice) and d male mice (lue: p<.1, Student s t-test, n= control mice and n= 1 GlcN-fed mice) on a GlcN-containing diet in comparison to control mice (lack: interaction etween gender and treatment, two-way ANOVA, F (1,33)= 1.9, p=., n= 1 control mice and n= 19 GlcN-fed mice). e Hepatic levels of GlcN--phosphate in female (lue: p<., Student s t-test, n= control mice and n= GlcN-fed mice) and f male mice (lack: interaction etween gender and treatment, two-way ANOVA, F (1,1)= 1.7, p=.31, n= 1 control mice and n= 1 GlcN-fed mice). g-l Body mass (lack: interaction etween gender and treatment, two-way ANOVA, F (1,3)=.71, p=.19, n= 1 control mice and n= GlcN-fed mice), ody fat (lack: interaction etween gender and treatment, twoway ANOVA, F (1,3)=., p=.13, n= 1 control mice and n= GlcN-fed mice) and lean mass (lack: interaction etween gender and treatment, two-way ANOVA, F (1,3)= 1.1, p=., n= 1 control mice and n= GlcN-fed mice) female and male mice. m-n Relative content of mitochondrial DNA in liver specimen of m female (lue: p<.1, Student s t-test, n= control mice and n= GlcN-fed mice) and n male mice (lack: interaction etween gender and treatment, two-way ANOVA, F (1,1)= 11.39, p=.3, n= 1 control mice and n= 13 GlcN-fed mice). o-p Energy expenditure normalized to metaolic ody mass of o female (lue: p=.9, Student s t-test, n= 1 control mice and n= 1 GlcN-fed mice) and p male mice calculated means for every hour during day, grey area reflects dark phase of the light cycle (lack: interaction etween gender and treatment, two-way ANOVA, F (1,33)= 3.1, p=., n= 17 control mice and n= GlcN-fed mice). Controls are always depicted in lack and grey color, whereas GlcN-treatment is depicted in red. The ars represent the mean + s.d.

Supplementary Figure 3 a c f i l 1 1 1 1 Time After Glucose Injection [min] 1 1 3 1 g m d 1 p=. p=. Random 1 Fasted fed 1 1 1 1 Time After Glucose Injection [min] 1 1 3 1 e 1 Random 1 Fasted fed 1 1 1 1 Time After Glucose Injection [min] 1 1 j k * * * 1 Time after Insulin Injection [min] p interact. =.9 p interact. =. h p interact. =. p interact. =.1 3 1 1 1 Time after Insulin Injection [min] Time after Insulin Injection [min] p n interact. =.7 p interact. =.3 * * o Triglyceride/ Protein u Cholesterol 3 1 1. 1..... 1. 1... p v Cholesterol Triglyceride/ Protein 1. 1..... 1. 1... q p interact. =.7 Triglyceride/ Protein r.... w p interact. =.9 x y z p interact. =.. 1 1 1. 1. 1 1 1 1... Cholesterol 3 1 1. 1.. FFA ALT [U/I].. 1. 1.. s FFA ALT [U/I] 3 1.. 1. 1.. t ALT [U/I] 7 p interact. =.3.. 1. 1.. FFA

Supplementary Figure 3 continued Supplementary Figure 3: Sex specific results of mouse phenotyping part a Blood glucose values of female mice chronically exposed to GlcN (red) in the random fed (lue: p=., Student s t-test, n= 1 control mice and n= 1 GlcN-fed mice) and fasted state (lue: p=., Student s t-test, n= 1 control mice and n= 1 GlcN-fed mice). Blood glucose values of male mice chronically exposed to GlcN (red) in the random fed and fasted state (lack: interaction etween gender and treatment, two-way ANOVA, random fed: F (1,3)=., p=.9, n= control mice and n= GlcN-fed mice, fasted: F (1,3)=.3, p=., n= control mice and n= GlcN-fed mice). c-h Glucose tolerance tests in mice chronically exposed to GlcN (red). g asolute (left y-axis) and relative values (right y-axis) for the area under lood glucose curve (AUC) for female and h male mice after chronically exposed to GlcN (red) (interaction etween gender and treatment, two-way ANOVA, asolute AUC: F (1,3)= 1., p=., n= 17 control mice and n= 1 GlcN-fed mice, relative AUC: F (1,3)=.3, p=.1, n= 17 control mice and n= 1 GlcN-fed mice. i-n insulin tolerance tests in mice chronically exposed to GlcN (red). i Blood glucose at asal level and 1, 3,,, 7 and 9 min after insulin injection comined for female and male mice (lue: p<., Student s t-test, n= 1 control mice and n= 1 GlcN-fed mice). Blood glucose at asal level and 1, 3,,, 7 and 9 min after insulin injection for j female and k male (lue: p<., Student s t-test, n= control mice and n= GlcN-fed mice). m asolute (left y-axis) and relative values (right y-axis) for the area under lood glucose curve (AUC) for female and n male mice after chronically exposed to GlcN (red) (interaction etween gender and treatment, two-way ANOVA, asolute AUC: F (1,3)=.1, p=.7, n= 1 control mice and n= 1 GlcN-fed mice, relative AUC: F (1,3)=.1, p=.3, n= 1 control mice and n= 1 GlcN-fed mice. o-q Plasma levels of triglycerides of p female and q male mice and o oth sexes in a comined manner chronically exposed to GlcN (red) (interaction etween gender and treatment, two-way ANOVA, F (1,3)=., p=.7, n= control mice and n= GlcN-fed mice. r-t Plasma level of non-esterified/free fatty acids for oth r female and male mice comined, as well as for oth sexes each (s females; t males) (interaction etween gender and treatment, two-way ANOVA, F (1,3)=.7, p=.3, n= control mice and n= GlcN-fed mice.) u-w Plasma level of total cholesterol for oth u female and male mice comined, as well as for oth sexes each (v females; w males) (interaction etween gender and treatment, two-way ANOVA, F (1,3)=.3, p=.9, n= control mice and n= GlcN-fed mice.) x-z Plasma level of alanine-aminotransferase for oth x female and male mice comined, as well as for oth sexes each (y females; z males) (interaction etween gender and treatment, two-way ANOVA, F (1,3)=.1, p=., n= control mice and n= GlcN-fed mice.) Controls are always depicted in lack and grey color, whereas GlcN-treatment is depicted in red. The ars represent the mean + s.d.

Supplementary Figure a c d e f p interact. =.33 p interact. =.3 UDP-GlcNAc 3x1 x1 1x1 UDP-GlcNAc 3x1 x1 1x1 UDP-GlcNAc 3x1 x1 1x1 Urea 1 Urea 1 p=.7 Urea 1 g h i j k l p interact. =.3 p interact. =.11 p interact. =. Succinate x1 3x1 x1 1x1 * Succinate x1 3x1 x1 1x1 CH 3 -utanoyl-coa 3x1 x1 1x1 p=.7 CH 3 -utanoyl-coa 3x1 x1 1x1 CH 3 -crotonyl-coa.x1 1.x1 1.x1.x1 ** CH 3 -crotonyl-coa.x1 1.x1 1.x1.x1 Supplementary Figure : Sex specific results of mouse phenotyping part 3 a-c Concentrations of UDP-N-acetyl-D-glucosamine in liver samples of treated and untreated mice a oth female and male mice comined, as well as for oth sexes each ( females; males) (interaction etween gender and treatment, two-way ANOVA, F (1,1)=., p=.33, n= control mice and n= GlcN-fed mice.) d Urea plasma levels of mice chronically exposed to GlcN (red). e Urea plasma levels of female mice (lue: p=.7, Student s t-test, n= 9 control mice and n= 9 GlcN-fed mice) and f male mice (interaction etween gender and treatment, two-way ANOVA, F (1,3)=., p=.3, n= 1 control mice and n= 1 GlcN-fed mice.) g liver succinate levels of female (lue: p<., Student s t-test, n= control mice and n= GlcN-fed mice) and h male mice (interaction etween gender and treatment, twoway ANOVA, F (1,1)= 1., p=.3, n= 1 control mice and n= 1 GlcN-fed mice.) i Hepatic levels of methyl-utanoyl-coa of female (lue: p=.7, Student s t-test, n= control mice and n= GlcN-fed mice) and j male mice (interaction etween gender and treatment, two-way ANOVA, F (1,1)=.79, p=.11, n= 1 control mice and n= 1 GlcN-fed mice.) k levels of methyl-crotonyl-coa in liver specimen of control and GlcN-fed female (lue: p<.1, Student s t-test, n= control mice and n= GlcN-fed mice) and l male mice, respectively (interaction etween gender and treatment, two-way ANOVA, F (1,1)=.7, p=., n= 1 control mice and n= 1 GlcN-fed mice.). Controls are always depicted in grey color, whereas GlcN-treatment is depicted in red. The ars represent the mean + s.d.

Supplementary Figure aak- ctrl GlcN ctrl GlcN pmk-1 a KO h h 1h 1h KO c aak- ctrl GlcN ctrl GlcN pmk-1 KO h h 1h 1h KO p-ampk aak- N (wt) ctrl GlcN p-ampk ( kda) ( kda) ( kda) ( kda) d e pmk-1 ctrl GlcN KO h h f pmk-1 ctrl GlcN KO h h pmk-1 N (wt) p-p3 ctrl GlcN (3 kda) ( kda) p-p3 (3 kda) ( kda) g h GlcN (h).. 1 1 3 3 GlcN (h).. 1 1 3 3 p-ampk ( kda) p3 AMPK AMPK ( kda) (3 kda) ( kda) p-p3 (3 kda) p3 (3 kda) ( kda) GlcN (h) i GlcN (h).. 1 1 3 3.. 1 1 3 3 j GlcN (h).. 1 1 3 3 p-ampk ( kda) ( kda) p-p3 (3 kda)

Supplementary Figure continued Supplementary Figure : Memrane scans of Western lots depicted in manuscript main figures a-f Immunolotting against phospho-ampk und phospho-p3 in aak--ko, pmk-1-ko and wildtype worms treated with GlcN and respective controls. Immunolotting against α-tuulin was used to normalize protein amount. g-j Immunolotting against phospho-ampk, total AMPK, phospho-p3 and total p3 in HepG-cells treated with GlcN. Immunolotting against α-tuulin was used to normalize protein amount. The memranes showing immunolotting of HepG cells were used to detect the signal of several memranes using the same antiody.

Supplementary Tale 1 RNAi Sequences F1D.1 cdna (ORF) ATGGATCTCACTGTTCCAGTTGAATATTCACGTGCCGGTAACACAACTCACAGCGGTAATGTGCATGCCATTCAAGA CGATGAGAAATTCTCGTATGGAACTGCTGGATTCCGATTCAAGTCCGAGAAGCTTCCATTCATCGTCTTCCGGTGTGC TTACGTTGCGAGTCTTCGTGCGCGGCAGCTCAACTCAGCTATCGGAGTGATGATTACAGCTTCACACAATCCATCATG TGACAATGGTGTGAAATTAGTGGATCCAAGTGGCGATATGCTCAATGAGCAGTGGGAGATATACGCGACTGAAGTTGT GAATGCTACTGATGCCGAGCTCCCAGCCGCAGTTCGAGCTCTTGAAAAACAAATTTCAGTCGGAAAGACCCAACTTTC CCGTGTCGTTTGTGGTATGGACACACGTTGCTCTGGTCCTTGTCTGATGAATGCAGCAAGAGCCGGTGCAGCGTTATT CAATGTACAATTCGATGATATCGGTGTTGTGTCGACTCCAATGCTTCATTATGCTGTCAAGGCATTCAACGAGCCAAAA TTCGCAGAGCCAACTCACGATGGATATTATTCTGCAATCGCCGATTCGTTCAAGAAGCTGTATGAAATAACTGAGGAAC CCAAAGACTCGAGATATCAACCAAAAGTCATTGTCGATTGCGCAAACGGAGTCGGTGCTCCACGGTTCAGAAATCTTC TTGAGCGAATCCCATCATCACTTCTGGAAGTTGAATTTCGTAATGAATCGGAAGAACTGAATCAGGGATGTGGTGCCG ATTTCGTTAAGATTTCGCAAAAGTTACCAGCAAACTTCTCACCGACAGCAGCAGAACCAAAATGTGCTTCATTTGATGG AGATGCCGATCGCTTGATGTACTTCCGTGCAAAGGCTTCAGAAAATTCGGAATCAAACGATGCTGAGCTGTTCGACGG TGACAAAATTGCAGTTCTGATTGTCACATACATTCGGGAGCAACTGAAGGATTACGAAAATTCCACTCCGATGGAACGT CTCCGCCTTGGTATTGTTCAAACAGCATATGCGAATGGAAGTTCAACACGCTACATTCGTGAAAAGTTGGGTATTGAGC CAATTATTGTACCTACTGGAGTCAAGCATCTGCATGAAGCTGCTTCTGAGTTCGACATTGGAATTTATTTCGAGGCCAA CGGACACGGAACTGTTGTTTTCAGCGAGATTTTCGACCGCATCATCAGAAGAACTCCAACTGAATCATTACCTCTCCGT CGTCTAGCACTTTTCTCCCGTGTCATCAATGAAACTGTTGGGGATGCTTTTGCAGATTTGCTTGCCGTGGAAGCTGTTC TCCGTCACTATGGATGGTCTATGGATGACTGGGCCGAAAAACTGTATCGAGATGTTCCGAATGTGCAGATCAAAGTTC CAGTTATTGATCGTTCCATTTTCAAAACGACGAACGCCGAGCAAACTCTTGTGAAACCTGTTGGAATTCAAAAAATGAT TGATACGGATGTTGCAAAGTACAATAATTCGAGAGCTTTCATCAGACCATCTGGCACCGAGAACATTGTTCGCGTATAC GCTGAAGCGGATACTGTTGAAAATACATTGCAACTCGGAAAATCTCTCGAACAAGTCGTTCTCAACCTTTGCAACTCGA ACTGA aat-1 (Ahringer lirary) CAAGAGCGATACATCCAGCAAGGAAAATAGCTGGCCAAATGAGTGGAACTTTAATTGGTCTTGATGCATCTGGCATG GTTCTACGAAGCCAGAAGAGTGCGGCAATGGCTGTTCCGATTGCAAGCCAGTAACTGATCTAGAAAATGAAAGTTTCT TGTTCGAGAACATGCATATTTTTTGAAGCTTGAATTCAAGCTTCTAAAATTGATGCTTCAAGAAACTCAGTACCGGGAAA TATTAAAAAAAAAAAGCTATCACACTTACTTGAATATAATTAATCAATTGATACACATCCTTTGATGCCAACAAGTAAGCA ATAGAAAGAGCTCCGGTAAGAATAACAGCGGGAATCGGTGTTTTCGTTTTTTTATTAATCATTGTCAATACAGCTGGCA TTTGTCCTTCACGAGCACCGGAATAAAAAAGTCTCGCTGAAGTGAAAATAACTCCATTAGCTGATCCAATTGTGGAACA TGCAACACAGAGTGGCATAATAAATGCGAATTTTCCATAGAGTTTATTGGCGAAAAGTACCGCTACAGCCGGGGATTC GAGCATTTCATCTGGTGAAATTGCTGTGTAGAGAGCCACATTAGTTAGCACGTAGATTACGGTACAGGATGTGATAGA GATGGCAATTGCGAGTGGAAGGTTTCTGAAAATTATGGTATAAGAAAATAAATAATATATCGTTAAATTTTTTTTACTGTT TCATAATGCAATTAGAACCTAAAATAATTTGCTAGATTAATTGACAAGTATTCTACAACAGATTAAAGTAGACCAATAAAC TACTCATAGTCAGCTCTGAAACTTTAAATAAAAACAATTGGAATGTAAAAACTGTGTTAATGTGTTTCATGTAAACTATAC AATCACTGAAACTTACCGTTTTGGGTTCTGCAACTCCTCGACGATGAAATTCAAGAAATTCCATCCAGAATAAGCGAAT AATCCAGAGTAGAAAGCAAGTGAAACTTTTGTAAAATCTTGAGATGTATTCTCAAAAATATTCTCGAATGAGTCCTTGTA CTGAGATTCACCTGAAATTTTTTATATTTTCTAAATACAGAATAGCTTAAGTGCTCACCAAAGAAAAGGAGACCAAGTCC GGTTAAAATGATAAGACACAGAGCAACAACCTTTGCAA